Developing new drugs to treat illnesses has typically been a slow and expensive process. However, a team of researchers at ...

As with its predecessor, the new drug candidate, Jun13296, targets a different viral protein than Paxlovid does and works ...

The Icahn School of Medicine at Mount Sinai has launched the AI Small Molecule Drug Discovery Center, a bold endeavor that harnesses artificial intelligence (AI) to revolutionize drug development.

The new center will design novel drug-like molecules using generative AI and optimize existing compounds to enhance their ...

The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections, the first such drug ...

In attempt to keep R&D costs low, the vivarium business model has emerged as a crucial solution for drug developers.

The company is expanding its cardiology portfolio with a new treatment for transthyretin amyloid cardiomyopathy in Europe.

Previously unknown access points in cell membrane proteins have been discovered, enabling laboratory-developed drugs to modify cell function. The discovery was made possible through computer ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Cell membrane proteins hide secret gateways that can be used to modify cell behavior. This has been demonstrated in a study ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...

BullFrog AI plans to introduce what it considers a game-changing approach that could shorten timelines, reduce costs, and increase success rates in drug development.